+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Years - 17Years
All Genders
ID05776927

Evaluating QVM149 Versus Salmeterol XinafoateFluticasone Propionate in Children Aged 12 to Less Than 18 Years With Asthma Using a Two-Period Crossover Design

Led by Novartis Pharmaceuticals · Updated on 2026-10-15

188

Participants Needed

22

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying children aged 12 to less than 18 years with asthma to compare the safety and effectiveness of a combination inhaler called QVM149 which includes indacaterol acetate, glycopyrronium bromide, and mometasone furoate against another inhaler combining salmeterol xinafoate and fluticasone propionate. The study is designed as a randomized, double-blind, crossover trial lasting 36 weeks to see how these treatments affect lung function and asthma control. Participants will first go through a screening period up to 15 days, followed by a 14-day run-in phase using salmeterol xinafoate with fluticasone propionate. Then, they will receive two treatment periods of 12 weeks each one period with QVM149 once daily plus a placebo matching the comparator inhaler, and another period with the comparator inhaler twice daily plus a placebo matching QVM149. A 3-week washout period separates these treatment phases. After completing treatments, participants enter a 30-day safety follow-up while returning to their usual asthma care. During the study, participants will attend regular visits to assess lung function using FEV1 measurements, asthma control through questionnaires, quality of life, and rescue medication use. Researchers will also track any asthma exacerbations and monitor safety by recording adverse events throughout the treatment and follow-up. The total study duration for each participant is approximately 36 weeks.

CONDITIONS

Brief Title

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here